<DOC>
	<DOC>NCT01755104</DOC>
	<brief_summary>The purpose of the study is to evaluate the impact of the intake of a dietary supplement STABLOR™ on the change of the abdominal visceral fat mass in patients with a metabolic syndrome.</brief_summary>
	<brief_title>Effect of Stablor on Visceral Fat Loss in Patients With a Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<criteria>With a Body Mass Index (BMI) more than or equal to 25 kg/m² and less than 40 kg/m², With a metabolic syndrome characterized by a a waist circumference of more than 94 cm for the males (90 cm for SouthAsians, Chinese and Japanese) and more than 80 cm for the females, and at least 2 of the following criteria : Arterial Blood pressure &gt; or = 130 mmHg (systolic) and/or more than or equal to 85 mmHg (diastolic) or stabilized with treatment for at least 6 months, Fasting glycemia &gt; or = 1 g/L or 5.6 mmol/L or stabilized with treatment for at least 6 months and nondiabetic &lt; 1.26 g/L, Triglycerides &gt; or = 1.5 g/L or 1.71 mmol/L or stabilized with treatment for at least 6 months, HDL Cholesterol &lt;0.40 g/L or 1.03 mmol/L (males) and &lt;0,5 g/l or 1.29 mmol/L (females) or stabilized with treatment for at least 6 months. Pregnant (positive pregnancy test at the selection visit or breastfeeding woman, Woman of childbearing potential without an efficient contraception method, The above information is not intended to contain all considerations relevant to a patient's potential participation in the clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>